☰

Thomas V. Riera, Ph.D. - Publications

Affiliations: 
2007 Biochemistry Brandeis University, Waltham, MA, United States 
Area:
Biochemistry
Tree Info Grants Similar researchers PubMed Report error

23 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Thomenius MJ, Totman J, Harvey D, Mitchell LH, Riera TV, Cosmopoulos K, Grassian AR, Klaus C, Foley M, Admirand EA, Jahic H, Majer C, Wigle T, Jacques SL, Gureasko J, et al. Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferation. Plos One. 13: e0197372. PMID 29856759 DOI: 10.1371/Journal.Pone.0197372  0.348
2018 Thomenius MJ, Totman J, Cosmopoulos K, Brach D, Ci L, Farrow N, Smith JJ, Chesworth R, Duncan KW, Tang C, Riera T, Lampe J. Identification of a First-in-Class SETD2 Inhibitor That Shows Potent and Selective Anti-Proliferative Activity in t(4;14) Multiple Myeloma: T(4;14) Multiple Myeloma Cells Are Dependent on Both H3K36 Di and Tri-Methylation Blood. 132: 3207-3207. DOI: 10.1182/Blood-2018-99-110803  0.316
2017 Drew AE, Moradei O, Jacques SL, Rioux N, Boriack-Sjodin AP, Allain C, Scott MP, Jin L, Raimondi A, Handler JL, Ott HM, Kruger RG, McCabe MT, Sneeringer C, Riera T, et al. Identification of a CARM1 Inhibitor with Potent In Vitro and In Vivo Activity in Preclinical Models of Multiple Myeloma. Scientific Reports. 7: 17993. PMID 29269946 DOI: 10.1038/S41598-017-18446-Z  0.349
2016 Riera TV, Wigle TJ, Copeland RA. Characterization of Inhibitor Binding Through Multiple Inhibitor Analysis: A Novel Local Fitting Method. Methods in Molecular Biology (Clifton, N.J.). 1439: 33-45. PMID 27316986 DOI: 10.1007/978-1-4939-3673-1_2  0.356
2016 Jacques SL, Aquino KP, Gureasko J, Boriack-Sjodin PA, Porter Scott M, Copeland RA, Riera TV. CARM1 Preferentially Methylates H3R17 over H3R26 through a Random Kinetic Mechanism. Biochemistry. PMID 26848779 DOI: 10.1021/Acs.Biochem.5B01071  0.351
2016 Basavapathruni A, Gureasko J, Porter Scott M, Hermans W, Godbole A, Leland PA, Boriack-Sjodin PA, Wigle TJ, Copeland RA, Riera TV. Characterization of the Enzymatic Activity of SETDB1 and its 1:1 Complex with ATF7IP. Biochemistry. PMID 26813693 DOI: 10.1021/Acs.Biochem.5B01202  0.376
2015 Dai H, Case AW, Riera TV, Considine T, Lee JE, Hamuro Y, Zhao H, Jiang Y, Sweitzer SM, Pietrak B, Schwartz B, Blum CA, Disch JS, Caldwell R, Szczepankiewicz B, et al. Crystallographic structure of a small molecule SIRT1 activator-enzyme complex. Nature Communications. 6: 7645. PMID 26134520 DOI: 10.1038/Ncomms8645  0.402
2015 Jacques SL, Aquino KP, Gureasko J, Boriack-Sjodin PA, Copeland RA, Riera TV. Abstract 97: CARM1 preferentially methylates H3R17 over H3R26 through a random kinetic mechanism Cancer Research. 75: 97-97. DOI: 10.1158/1538-7445.Am2015-97  0.351
2015 Riera TV, Wigle TJ, Gureasko J, Boriack-Sjodin PA, Copeland RA. Abstract 2144: Kinetic mechanism of the lysine methyltransferase SMYD3 using MAP3K2 protein substrate Cancer Research. 75: 2144-2144. DOI: 10.1158/1538-7445.Am2015-2144  0.325
2015 Basavapathruni A, Gureasko J, Scott MP, Boriack-Sjodin PA, Wigle TJ, Riera TV, Copeland RA. Abstract 104: ATF7IP does not alter the substrate specificity of the lysine methyltransferase SETDB1 Cancer Research. 75: 104-104. DOI: 10.1158/1538-7445.Am2015-104  0.349
2015 Mitchell LH, Boriack-Sjodin PA, Smith S, Thomenius M, Rioux N, Munchhof M, Mills JE, Klaus C, Totman J, Riera TV, Raimondi A, Jacques SL, Foley M, Waters NJ, Kuntz KW, et al. Abstract C85: Identification of a novel potent selective SMYD3 inhibitor with oral bioavailability Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-C85  0.341
2015 Grassian AR, Fowler J, Feldman I, Riera T, Harvey D, Drew AE, Chesworth R, Copeland RA, Keilhack H, Smith JJ, Ribich S. Abstract B78: CRISPR pooled screening identifies differential dependencies on epigenetic pathways Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-B78  0.301
2013 Hubbard BP, Gomes AP, Dai H, Li J, Case AW, Considine T, Riera TV, Lee JE, E SY, Lamming DW, Pentelute BL, Schuman ER, Stevens LA, Ling AJ, Armour SM, et al. Evidence for a common mechanism of SIRT1 regulation by allosteric activators. Science (New York, N.Y.). 339: 1216-9. PMID 23471411 DOI: 10.1126/Science.1231097  0.377
2011 Riera TV, Zheng L, Josephine HR, Min D, Yang W, Hedstrom L. Allosteric activation via kinetic control: potassium accelerates a conformational change in IMP dehydrogenase. Biochemistry. 50: 8508-18. PMID 21870820 DOI: 10.1021/Bi200785S  0.58
2010 Dai H, Kustigian L, Carney D, Case A, Considine T, Hubbard BP, Perni RB, Riera TV, Szczepankiewicz B, Vlasuk GP, Stein RL. SIRT1 activation by small molecules: kinetic and biophysical evidence for direct interaction of enzyme and activator. The Journal of Biological Chemistry. 285: 32695-703. PMID 20702418 DOI: 10.1074/Jbc.M110.133892  0.386
2010 Macpherson IS, Kirubakaran S, Gorla SK, Riera TV, D'Aquino JA, Zhang M, Cuny GD, Hedstrom L. The structural basis of Cryptosporidium -specific IMP dehydrogenase inhibitor selectivity. Journal of the American Chemical Society. 132: 1230-1. PMID 20052976 DOI: 10.1021/Ja909947A  0.587
2008 Riera TV, Wang W, Josephine HR, Hedstrom L. A kinetic alignment of orthologous inosine-5'-monophosphate dehydrogenases. Biochemistry. 47: 8689-96. PMID 18642884 DOI: 10.1021/Bi800674A  0.634
2008 Umejiego NN, Gollapalli D, Sharling L, Volftsun A, Lu J, Benjamin NN, Stroupe AH, Riera TV, Striepen B, Hedstrom L. Targeting a prokaryotic protein in a eukaryotic pathogen: identification of lead compounds against cryptosporidiosis. Chemistry & Biology. 15: 70-7. PMID 18215774 DOI: 10.1016/J.Chembiol.2007.12.010  0.585
2008 Umejiego NN, Gollapalli D, Sharling L, Volftsun A, Lu J, Benjamin NN, Stroupe AH, Riera TV, Striepen B, Hedstrom L. Targeting a Prokaryotic Protein in a Eukaryotic Pathogen: Identification of Lead Compounds against Cryptosporidiosis (DOI:10.1016/j.chembiol.2007.12.010) Chemistry and Biology. 15: 200. DOI: 10.1016/j.chembiol.2008.02.007  0.482
2004 Umejiego NN, Li C, Riera T, Hedstrom L, Striepen B. Cryptosporidium parvum IMP dehydrogenase: identification of functional, structural, and dynamic properties that can be exploited for drug design. The Journal of Biological Chemistry. 279: 40320-7. PMID 15269207 DOI: 10.1074/Jbc.M407121200  0.613
2004 Zhang Y, Heinsen MH, Kostic M, Pagani GM, Riera TV, Perovic I, Hedstrom L, Snider BB, Pochapsky TC. Analogs of 1-phosphonooxy-2,2-dihydroxy-3-oxo-5-(methylthio)pentane, an acyclic intermediate in the methionine salvage pathway: a new preparation and characterization of activity with E1 enolase/phosphatase from Klebsiella oxytoca. Bioorganic & Medicinal Chemistry. 12: 3847-55. PMID 15210152 DOI: 10.1016/J.Bmc.2004.05.002  0.597
2004 Guillén Schlippe YV, Riera TV, Seyedsayamdost MR, Hedstrom L. Substitution of the conserved Arg-Tyr dyad selectively disrupts the hydrolysis phase of the IMP dehydrogenase reaction. Biochemistry. 43: 4511-21. PMID 15078097 DOI: 10.1021/Bi035823Q  0.578
2003 Hedstrom L, Gan L, Schlippe YG, Riera T, Seyedsayamdost M. IMP dehydrogenase: the dynamics of drug selectivity. Nucleic Acids Research. Supplement (2001). 97-8. PMID 14510398 DOI: 10.1093/nass/3.1.97  0.63
Show low-probability matches.